XML 53 R42.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stockholders' Equity - Equity Issuances (Details)
 1 Months Ended 6 Months Ended 12 Months Ended 25 Months Ended
Sep. 14, 2016
USD ($)
clinical_trial_subject
$ / shares
Feb. 28, 2018
USD ($)
shares
Nov. 30, 2015
USD ($)
shares
Jun. 30, 2018
USD ($)
shares
Dec. 31, 2017
USD ($)
shares
Dec. 31, 2016
shares
Nov. 30, 2017
shares
Aug. 09, 2018
USD ($)
Class of Stock [Line Items]                
Shares issued, price (in usd per share) | $ / shares $ 4.72              
Private Purchase Agreement [Member]                
Class of Stock [Line Items]                
Proceeds from issuance of common stock, initial closing $ 6,600,000              
Proceeds from issuance of common stock, second closing         $ 4,400,000      
Stock issued (shares) | shares         900,000 1,400,000    
Number of subjects for Phase 2 CLBS03 clinical trial, second closing | clinical_trial_subject 70              
Aspire Capital Purchase Agreement [Member]                
Class of Stock [Line Items]                
Stock issued (shares) | shares             319,776  
Proceeds from issuance of stock     $ 1,500,000          
Purchase commitment, remaining minimum amount committed     $ 30,000,000          
Purchase commitment, maximum amount committed (shares) | shares     1,100,000          
Term of agreement in months     24 months          
H.C. Wainwright Sales Agreement [Member]                
Class of Stock [Line Items]                
Stock issued (shares) | shares       34,215        
Proceeds from issuance of stock       $ 200,000        
Aggregate offering amount authorized per agreement   $ 12,000,000   $ 12,000,000        
Maximum number of shares authorized per agreement | shares   2,790,697            
Commission on gross proceeds due to third party (percent)   3.00%            
Legal fees reimbursed to third party   $ 50,000            
Quarterly filing fees payable, maximum   $ 2,500            
Subsequent Event [Member] | H.C. Wainwright Sales Agreement [Member]                
Class of Stock [Line Items]                
Aggregate offering amount authorized per agreement               $ 25,000,000